People
In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
Since taking over as chief executive officer of Swiss pharma giant Novartis, Vas Narasimhan has been actively reshaping the company to focus on therapies that will drive revenue well into the future.
David Johnston, the former chief financial officer of AVEO Oncology, was found guilty of misleading investors about the company’s kidney cancer drug, Tivozanib. Under new leadership, AVEO aims to seek U.S. approval for its kidney cancer drug early next year.
Assembling a diverse portfolio of therapeutic peptides targeting clinical indications with high unmet need
Developing Targeted Therapies With Potential Applicability Across Many Cancer Types
Azeria Therapeutics Limited, a newly formed drug discovery company, today announced the appointment of Dr Julian Blagg as VP Drug Discovery.
Sareum Holdings plc is pleased to announce the appointments of Michael Owen, PhD and Clive Birch as Non-Executive Directors.
One company, Life Biosciences, is taking a broad—yet also specific—approach to longevity and diseases of aging. Co-founder and chairman David Sinclair took time to talk to BioSpace about the company.
Seven African American seek unspecified damages over allegations of discrimination at Charleston, S.C. facility.
Consilium Strategic Communications today announces the appointment of Alex Harrison as a Senior Advisor.
PRESS RELEASES